RBC Capital analyst Gregory Renza lowered the firm’s price target on Jasper Therapeutics to $68 from $70 and keeps an Outperform rating on the shares after its Q2 results. The company provided the updated timeline for briq’s initial BEACON readout – now confirmed for Q4 of this year vs. Q3 previous forecast – and with a new 180mg Q8W dose cohort added, the analyst tells investors in a research note. Strong enrollment rate enabled more robust data generation and presentation from all dose cohorts and net/net, the totality of the dataset and the potential for optimal dose selection from this readout more than offset any optics of slightly pushed-back data timeline, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics reports Q2 EPS (97c), consensus ($1.09)
- Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
- Jasper Therapeutics, Inc. (JSPR) Q2 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 7/9/2024, According to Top Analysts
- Jasper Therapeutics initiated with a Buy at BTIG